Effect of recombinant human bone morphogenetic protein-2/absorbable collagen sponge (rhBMP-2/ACS) on healing in 3-wall intrabony defects in dogs.
BACKGROUND
Recombinant human bone morphogenetic protein-2 (rhBMP-2) in an absorbable collagen sponge (ACS) carrier is being evaluated as a candidate therapy for periodontal regeneration. The objective of this study was to evaluate regeneration of alveolar bone and cementum, and associated root resorption and ankylosis following surgical implantation of rhBMP-2/ACS in a canine clinical model.


METHODS
Bilateral 3-wall intrabony periodontal defects were surgically induced in the premolar region in the maxilla and mandible in 8 young adult Korean mongrel dogs. The defects in each animal received rhBMP-2/ACS (rhBMP-2 at 0.2 mg/ml, total implant volume/defect approximately 0.1 ml) or buffer/ACS, or served as sham-operated controls. Surgeries were sequenced for each animal to provide postmortem observations following 8- and 24-week healing intervals. Treatment outcomes were evaluated using clinical, radiographic, and histometric parameters.


RESULTS
Surgical implantation of rhBMP-2/ACS resulted in accelerated enhanced bone formation in the 3-wall intrabony periodontal defects but in no apparent enhancement of cementum regeneration. rhBMP-2/ACS did not appear to be associated with aberrant healing events such as root resorption and ankylosis under these simulated clinical conditions.


CONCLUSIONS
Surgical implantation of rhBMP-2/ACS may be used safely to support regeneration of alveolar bone in intrabony periodontal defects in dogs without aberrant events such as root resorption or ankylosis complicating the regenerative procedure. rhBMP-2/ACS does not appear to have a significant effect on cementum regeneration and formation of a functional periodontal ligament in this model.
Choi
Seong-Ho
SH
Department of Periodontology, Research Institute for Periodontal Regeneration, College of Dentistry, Yonsei University, Seoul.
Kim
Chong-Kwan
CK
Cho
Kyoo-Sung
KS
Huh
Ji-Sun
JS
Sorensen
Rachel G
RG
Wozney
John M
JM
Wikesjö
Ulf M E
UM
D016301:Alveolar Bone Loss / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D000539:Alveolar Process / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology; D000704:Analysis of Variance; D000818:Animals; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D001861:Bone Regeneration / Q000187:drug effects; D003238:Connective Tissue / Q000187:drug effects / Q000473:pathology; D003739:Dental Cementum / Q000187:drug effects / Q000473:pathology; D004285:Dogs; D004337:Drug Carriers; D004343:Drug Implants; D004846:Epithelial Attachment / Q000187:drug effects / Q000473:pathology; D005500:Follow-Up Studies; D005781:Gelatin Sponge, Absorbable; D006801:Humans; D010012:Osteogenesis / Q000187:drug effects; D010513:Periodontal Ligament / Q000187:drug effects; D011859:Radiography; D011994:Recombinant Proteins; D012391:Root Resorption / Q000209:etiology; D013223:Statistics as Topic; D020254:Tooth Ankylosis / Q000209:etiology; D016212:Transforming Growth Factor beta / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects
C525718:BMP2 protein, human; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D004337:Drug Carriers; D004343:Drug Implants; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2